Market open
bluebird bio/$BLUE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About bluebird bio
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Ticker
$BLUE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
282
Website
bluebird bio Metrics
BasicAdvanced
$76M
Market cap
-
P/E ratio
-$1.68
EPS
0.80
Beta
-
Dividend rate
Price and volume
Market cap
$76M
Beta
0.8
52-week high
$3.58
52-week low
$0.29
Average daily volume
9.4M
Financial strength
Current ratio
0.509
Quick ratio
0.287
Long term debt to equity
-3,002.61
Total debt to equity
-6,482.942
Interest coverage (TTM)
-15.24%
Management effectiveness
Return on assets (TTM)
-36.91%
Return on equity (TTM)
-270.20%
Valuation
Price to revenue (TTM)
1.289
Price to book
-13.12
Price to tangible book (TTM)
-3.58
Price to free cash flow (TTM)
-0.252
Growth
Revenue change (TTM)
144.50%
Earnings per share change (TTM)
169.55%
3-year revenue growth (CAGR)
-39.34%
3-year earnings per share growth (CAGR)
-49.24%
What the Analysts think about bluebird bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for bluebird bio stock.
bluebird bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
bluebird bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
bluebird bio News
AllArticlesVideos
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire·4 days ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire·5 days ago
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for bluebird bio stock?
bluebird bio (BLUE) has a market cap of $76M as of December 12, 2024.
What is the P/E ratio for bluebird bio stock?
The price to earnings (P/E) ratio for bluebird bio (BLUE) stock is 0 as of December 12, 2024.
Does bluebird bio stock pay dividends?
No, bluebird bio (BLUE) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next bluebird bio dividend payment date?
bluebird bio (BLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for bluebird bio?
bluebird bio (BLUE) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.